Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page




    Remdesivir but not famotidine inhibits SARS-CoV-2 replication in human pluripotent stem cell-derived intestinal organoids

    Authors: Jan Krueger; Ruediger Gross; Carina Conzelmann; Janis A Mueller; Lennart Koepke; Konstantin Sparrer; Desiree Schuetz; Thomas Seufferlein; Thomas F.E. Barth; Steffen Stenger; Sandra Heller; Alexander Kleger; Jan Muench

    doi:10.1101/2020.06.10.144816 Date: 2020-06-11 Source: bioRxiv

    Gastrointestinal symptoms in COVID-19 MESHD are associated with prolonged symptoms and increased severity. We employed human intestinal organoids derived from pluripotent stem cells ( PSC-HIOs MESHD) to analyze SARS-CoV-2 pathogenesis and to validate efficacy of specific drugs in the gut. Certain, but not all cell types in PSC-HIOs MESHD express SARS-CoV-2 entry factors ACE2 HGNC and TMPRSS2 HGNC, rendering them susceptible to SARS-CoV-2 infection MESHD. Remdesivir, a promising drug to treat COVID-19 MESHD, effectively suppressed SARS-CoV-2 infection of PSC-HIOs MESHD. In contrast, the histamine-2-blocker famotidine showed no effect. Thus, PSC-HIOs MESHD provide an interesting platform to study SARS-CoV-2 infection MESHD and to identify or validate drugs.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.